There’s also the concept of so-called “wildcard exclusivity” proposed in one version of the 21st Century Cures Act. A provision in the bill would allow a sponsor to convey a portion of its exclusivity to apply with respect to one or more other drugs (see our previous post here). Such conveyance could include the sale of exclusivity from one company to another company and would also apply to Orange Book-listed patents.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.